Inactivating LATS2 Variation Drives Tumor Progression and Resistance to Anti-PD-1 Therapy in Intrahepatic Cholangiocarcinoma
Key Points
The aim is to explore the role of LATS2-inactivating variations in intrahepatic cholangiocarcinoma and their implications for therapy.
Observed clinical associations between LATS2 variation and tumor behavior.
Analyzed the effect of LATS2 inactivation on anti-PD-1 therapy response.
Found that LATS2-inactivating mutations correlate with increased tumor progression.
Demonstrated resistance to anti-PD-1 therapy in cases with LATS2 variations.
Abstract
Our study reveals a pivotal clinical association and mechanistic role of LATS2-inactivating variation in ICC, which may serve as a useful biomarker for precision therapy.